| Name | Title | Contact Details |
|---|
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Novarix is a collaborative medical device development company based near Oxford, UK and Raleigh, North Carolina, USA, delivering innovative new products in the field of venepuncture and cannulation to the worldwide healthcare sector. Novarix are proud to bring to market the IV-eye® – a portable, near infrared (NIR) vein imaging device which demonstrates the company ethos of practicality, simplicity and performance for both healthcare professionals and patients. The product idea came from a nursing perspective and has been developed in consultation with medical professionals in the UK and Denmark and with assistance from the biomedical engineering departments of Oxford University and University College London.
Medco Respiratory Instruments is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sutter Davis Hospital is a Davis, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Halyard Health is a medical technology company focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. We deliver clinically-superior products and solutions in infection prevention, surgical solutions, respiratory health, digestive health, pain management and IV therapy. Halyard Health became an independent company headquartered in Alpharetta, Georgia on November 1, 2014. Halyard operates 12 global manufacturing facilities with 16,500 employees worldwide – generating approximately $1.7 billion in net revenues. Halyard Health is traded on the New York Stock Exchange under the ticker symbol “HYH”.